CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Larimar Therapeutics, Inc. - LRMR CFD

    3.50
    3.24%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Larimar Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 3.39
    Open* 3.28
    1-Year Change* 9.33%
    Day's Range* 3.28 - 3.54
    52 wk Range 2.18-6.85
    Average Volume (10 days) 142.76K
    Average Volume (3 months) 2.41M
    Market Cap 135.23M
    P/E Ratio -100.00K
    Shares Outstanding 43.91M
    Revenue N/A
    EPS -0.76
    Dividend (Yield %) N/A
    Beta 0.50
    Next Earnings Date Mar 12, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 3.50 0.22 6.71% 3.28 3.54 3.25
    Nov 30, 2023 3.39 0.23 7.28% 3.16 3.43 3.16
    Nov 29, 2023 3.23 -0.15 -4.44% 3.38 3.46 3.14
    Nov 28, 2023 3.37 -0.01 -0.30% 3.38 3.48 3.28
    Nov 27, 2023 3.51 0.08 2.33% 3.43 3.52 3.32
    Nov 24, 2023 3.48 0.22 6.75% 3.26 3.58 3.26
    Nov 22, 2023 3.28 0.19 6.15% 3.09 3.28 2.97
    Nov 21, 2023 3.05 -0.05 -1.61% 3.10 3.16 3.01
    Nov 20, 2023 3.11 -0.17 -5.18% 3.28 3.28 3.04
    Nov 17, 2023 3.25 0.07 2.20% 3.18 3.41 3.15
    Nov 16, 2023 3.04 0.17 5.92% 2.87 3.17 2.71
    Nov 15, 2023 2.90 0.43 17.41% 2.47 2.95 2.47
    Nov 14, 2023 2.50 0.06 2.46% 2.44 2.71 2.43
    Nov 13, 2023 2.36 0.17 7.76% 2.19 2.38 2.18
    Nov 10, 2023 2.37 0.21 9.72% 2.16 2.40 2.15
    Nov 9, 2023 2.28 -0.42 -15.56% 2.70 2.70 2.23
    Nov 8, 2023 2.75 -0.11 -3.85% 2.86 2.95 2.71
    Nov 7, 2023 3.09 0.07 2.32% 3.02 3.13 2.95
    Nov 6, 2023 3.08 0.01 0.33% 3.07 3.15 2.98
    Nov 3, 2023 3.17 0.32 11.23% 2.85 3.17 2.85

    Larimar Therapeutics, Inc. Events

    Time (UTC) Country Event
    Tuesday, March 12, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q4 2023 Larimar Therapeutics Inc Earnings Release
    Q4 2023 Larimar Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Revenue 0 0
    Total Operating Expense 36.526 50.465 42.804 45.654 61.122
    Selling/General/Admin. Expenses, Total 12.276 12.069 11.397 16.215 13.193
    Research & Development 24.25 38.396 31.407 23.886 47.929
    Operating Income -36.526 -50.465 -42.804 -45.654 -61.122
    Interest Income (Expense), Net Non-Operating 0.248 -0.246
    Net Income Before Taxes -35.355 -50.636 -42.482 -45.406 -61.368
    Net Income After Taxes -35.355 -50.636 -42.482 -45.406 -61.368
    Net Income Before Extra. Items -35.355 -50.636 -42.482 -45.406 -61.368
    Net Income -35.355 -50.636 -42.482 -45.406 -61.368
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -35.355 -50.636 -42.482 -45.406 -61.368
    Income Available to Common Incl. Extra. Items -35.355 -50.636 -42.482 -45.406 -61.368
    Diluted Net Income -35.355 -50.636 -42.482 -45.406 -61.368
    Diluted Weighted Average Shares 25.7614 17.1643 11.8832 3.11227 2.68562
    Diluted EPS Excluding Extraordinary Items -1.3724 -2.95008 -3.57498 -14.5894 -22.8506
    Diluted Normalized EPS -1.3724 -2.95008 -3.57498 -12.8051 -22.8506
    Total Extraordinary Items
    Unusual Expense (Income) 5.553
    Other, Net 1.171 -0.171 0.322
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 9.62 7.637 10.439 8.513 8.687
    Selling/General/Admin. Expenses, Total 3.745 3.075 3.221 2.931 3.043
    Research & Development 5.875 4.562 7.218 5.582 5.644
    Operating Income -9.62 -7.637 -10.439 -8.513 -8.687
    Other, Net 1.254 1.111 1.014 0.193 0.02
    Net Income Before Taxes -8.366 -6.526 -9.425 -8.32 -8.667
    Net Income After Taxes -8.366 -6.526 -9.425 -8.32 -8.667
    Net Income Before Extra. Items -8.366 -6.526 -9.425 -8.32 -8.667
    Net Income -8.366 -6.526 -9.425 -8.32 -8.667
    Income Available to Common Excl. Extra. Items -8.366 -6.526 -9.425 -8.32 -8.667
    Income Available to Common Incl. Extra. Items -8.366 -6.526 -9.425 -8.32 -8.667
    Diluted Net Income -8.366 -6.526 -9.425 -8.32 -8.667
    Diluted Weighted Average Shares 43.8976 43.8976 44.0969 22.2282 18.3389
    Diluted EPS Excluding Extraordinary Items -0.19058 -0.14866 -0.21373 -0.3743 -0.4726
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.19058 -0.14866 -0.21373 -0.3743 -0.4726
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 120.739 72.204 97.952 71.503 121.33
    Cash and Short Term Investments 118.428 70.097 92.638 70.261 118.066
    Cash & Equivalents 26.825 70.097 68.148 27.211 49.331
    Short Term Investments 91.603 0 24.49 43.05 68.735
    Total Receivables, Net 0 0.208 0.243 1.536
    Prepaid Expenses 2.311 1.899 5.314 0.999 1.728
    Total Assets 126.405 78.667 104.686 80.734 121.762
    Property/Plant/Equipment, Total - Net 3.689 4.455 4.976 7.872 0.375
    Property/Plant/Equipment, Total - Gross 4.603 5.051 5.311 8.615 0.925
    Accumulated Depreciation, Total -0.914 -0.596 -0.335 -0.743 -0.55
    Other Long Term Assets, Total 1.977 2.008 1.758 1.359 0.057
    Total Current Liabilities 10.705 8.846 8.992 12.19 13.306
    Accounts Payable 1.686 1.66 2.634 0.632 3.59
    Accrued Expenses 9.019 7.186 6.358 4.285 4.261
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 7.273 5.455
    Total Liabilities 15.502 14.254 14.994 27.11 28.491
    Total Long Term Debt 0 0 0 8.464 15.185
    Long Term Debt 8.464 15.185
    Total Equity 110.903 64.413 89.692 53.624 93.271
    Redeemable Preferred Stock 0 0
    Common Stock 0.043 0.018 0.015 0.037 0.037
    Additional Paid-In Capital 262.496 180.645 155.29 449.903 444.212
    Retained Earnings (Accumulated Deficit) -151.605 -116.25 -65.614 -396.351 -350.945
    Other Equity, Total -0.031 0 0.001 0.035 -0.033
    Total Liabilities & Shareholders’ Equity 126.405 78.667 104.686 80.734 121.762
    Total Common Shares Outstanding 43.2692 17.7104 15.3677 3.12042 3.10714
    Other Liabilities, Total 4.797 5.408 6.002 6.456
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 98.48 106.478 113.464 120.739 127.127
    Cash and Short Term Investments 95.59 104.2 111.524 118.428 124.699
    Cash & Equivalents 38.721 94.321 111.524 26.825 86.047
    Short Term Investments 56.869 9.879 0 91.603 38.652
    Prepaid Expenses 2.89 2.278 1.94 2.311 2.314
    Total Assets 103.952 111.716 118.907 126.405 133.015
    Property/Plant/Equipment, Total - Net 3.499 3.255 3.472 3.689 3.906
    Property/Plant/Equipment, Total - Gross 4.643 4.323 4.464 4.603 4.742
    Accumulated Depreciation, Total -1.144 -1.068 -0.992 -0.914 -0.836
    Other Long Term Assets, Total 1.973 1.983 1.971 1.977 1.982
    Total Current Liabilities 6.558 7.275 8.01 10.705 9.42
    Accounts Payable 0.756 2.344 0.695 1.686 0.849
    Accrued Expenses 5.802 4.931 7.315 9.019 8.571
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 11.24 11.786 12.666 15.502 14.353
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 4.682 4.511 4.656 4.797 4.933
    Total Equity 92.712 99.93 106.241 110.903 118.662
    Redeemable Preferred Stock 0
    Common Stock 0.043 0.043 0.043 0.043 0.043
    Additional Paid-In Capital 268.223 266.372 264.329 262.496 260.839
    Retained Earnings (Accumulated Deficit) -175.561 -166.497 -158.131 -151.605 -142.18
    Other Equity, Total 0.007 0.012 0 -0.031 -0.04
    Total Liabilities & Shareholders’ Equity 103.952 111.716 118.907 126.405 133.015
    Total Common Shares Outstanding 43.9059 43.2692 43.2692 43.2692 43.2692
    Total Receivables, Net 0 0.114
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -35.355 -50.636 -42.482 -45.406 -61.368
    Cash From Operating Activities -27.569 -42.105 -42.199 -40.783 -51.487
    Cash From Operating Activities 0.318 0.326 0.155 0.263 0.261
    Non-Cash Items 5.845 5.458 2.171 4.745 9.027
    Cash Interest Paid 1.217 1.144
    Changes in Working Capital 1.623 2.747 -2.043 -0.385 0.593
    Cash From Investing Activities -90.96 24.169 17.09 25.263 -6.867
    Capital Expenditures -0.1 -0.333 -0.062 -0.764 -0.108
    Other Investing Cash Flow Items, Total -90.86 24.502 17.152 26.027 -6.759
    Cash From Financing Activities 75.257 19.885 93.587 -5.261 66.908
    Financing Cash Flow Items 0 17.995 0 -0.312
    Issuance (Retirement) of Stock, Net 75.257 19.885 75.592 0.194 67.22
    Issuance (Retirement) of Debt, Net -5.455 0
    Net Change in Cash -43.272 1.949 68.478 -20.781 8.554
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -6.526 -35.355 -25.93 -17.61 -8.943
    Cash From Operating Activities -7.551 -27.569 -20.897 -15.019 -7.533
    Cash From Operating Activities 0.078 0.318 0.24 0.163 0.082
    Non-Cash Items 1.217 5.845 4.91 3.307 1.635
    Changes in Working Capital -2.32 1.623 -0.117 -0.879 -0.307
    Cash From Investing Activities 92.25 -90.96 -38.726 -35.342 0
    Capital Expenditures -0.1 -0.1 -0.1
    Other Investing Cash Flow Items, Total 92.25 -90.86 -38.626 -35.242 0
    Cash From Financing Activities 0 75.257 75.573 0 0
    Financing Cash Flow Items 0 0 0
    Net Change in Cash 84.699 -43.272 15.95 -50.361 -7.533
    Issuance (Retirement) of Stock, Net 75.257 75.573
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Deerfield Management Company, L.P. Hedge Fund 39.1459 16941357 0 2023-06-30 MED
    Cowen Investment Management LLC Investment Advisor/Hedge Fund 7.8897 3414468 668203 2023-06-30 HIGH
    Verition Fund Management LLC Hedge Fund 6.2774 2716713 777891 2023-06-30 HIGH
    Janus Henderson Investors Investment Advisor/Hedge Fund 5.0636 2191411 745685 2023-08-10 LOW
    Woodline Partners LP Hedge Fund 3.8863 1681913 0 2023-06-30 HIGH
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.2155 1391601 100191 2023-06-30 LOW
    Opaleye Management Inc. Hedge Fund 3.2118 1390000 -11000 2023-06-30 MED
    BlackRock Institutional Trust Company, N.A. Investment Advisor 3.0264 1309766 991499 2023-06-30 LOW
    Citadel Advisors LLC Hedge Fund 2.7189 1176655 500217 2023-06-30 LOW
    Point72 Asset Management, L.P. Hedge Fund 1.9387 839000 384000 2023-06-30 HIGH
    Mangrove Partners Hedge Fund 1.862 805815 0 2023-06-30 MED
    Adage Capital Management, L.P. Hedge Fund 1.5058 651680 0 2023-06-30 LOW
    Hamilton (Thomas Edward) Individual Investor 1.4102 610313 0 2023-03-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.2398 536560 264596 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.9943 430317 324114 2023-06-30 LOW
    Two Sigma Investments, LP Hedge Fund 0.9371 405541 -52478 2023-06-30 HIGH
    UBS O'Connor LLC Hedge Fund 0.8399 363505 151011 2023-06-30 HIGH
    Dafna Capital Management, LLC Hedge Fund 0.8096 350373 113500 2023-06-30 LOW
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.7369 318909 153467 2023-06-30 LOW
    Atlas Venture Venture Capital 0.6751 292184 0 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Larimar Therapeutics, Inc. Company profile

    About Larimar Therapeutics Inc

    Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that is ineffective or no treatments available. Its cell penetrating peptide ( CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets that has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin ( FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in Phase I clinical program.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Larimar Therapeutics Inc revenues was not reported. Net loss increased 47% to $41.5M. Higher net loss reflects Research and Development increase of 50% to $30.6M (expense), Stock-based Compensation in SGA increase from $709K to $2.5M (expense), Stock-based Compensation in R&D increase from $442K to $1.5M (expense).

    Equity composition

    Common Stock, $0.001 Par, 06/14, auth. 115M shares,. 20,807,012 issd,. Insiders owns approx. 28.83%.

    Industry: Bio Therapeutic Drugs

    Three Bala Plaza East. Suite 506
    BALA CYNWYD
    PENNSYLVANIA 19004
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    BTC/USD

    38,841.75 Price
    -0.020% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    US100

    16,001.20 Price
    +0.470% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    XRP/USD

    0.62 Price
    +0.250% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Oil - Crude

    74.50 Price
    -1.560% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading